Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ALGS Aligos Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ALGS
Price (delayed)
$5.84
Market cap
$35.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.3
Enterprise value
-$30.29M
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver
Highlights
ALGS's quick ratio has surged by 178% since the previous quarter and by 22% year-on-year
Aligos Therapeutics's equity has surged by 95% YoY
ALGS's gross profit has dropped by 76% year-on-year and by 17% since the previous quarter
ALGS's revenue has dropped by 76% year-on-year and by 17% since the previous quarter
Key stats
What are the main financial stats of ALGS
Market
Valuations
Earnings
Shares outstanding
6.11M
Market cap
$35.71M
Enterprise value
-$30.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.31
Price to sales (P/S)
15.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-9.26
Revenue
$3.27M
Gross profit
$3.27M
Operating income
-$86.35M
Net income
-$53.26M
EBIT
-$70.99M
EBITDA
-$68.53M
Free cash flow
-$79.01M
Per share
Balance sheet
Liquidity
EPS
-$10.3
EPS diluted
-$17.53
Free cash flow per share
-$9.4
Book value per share
$19.04
Revenue per share
$0.39
TBVPS
$17.92
Total assets
$150.7M
Total liabilities
$34.25M
Debt
$7.87M
Equity
$116.45M
Working capital
$124.26M
Debt to equity
0.07
Current ratio
7.56
Quick ratio
7.28
Net debt/EBITDA
0.96
Margins
Efficiency
Dividend
EBITDA margin
-2,095.7%
Gross margin
100%
Net margin
-1,628.7%
Operating margin
-2,640.7%
Return on assets
-51%
Return on equity
-104%
Return on invested capital
-160.9%
Return on capital employed
-53.9%
Return on sales
-2,170.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALGS stock price
How has the Aligos Therapeutics stock price performed over time
Intraday
0.69%
1 week
30.36%
1 month
27.79%
1 year
-64.35%
YTD
-85.34%
QTD
-29.21%
Financial performance
How have Aligos Therapeutics's revenue and profit performed over time
Revenue
$3.27M
Gross profit
$3.27M
Operating income
-$86.35M
Net income
-$53.26M
Gross margin
100%
Net margin
-1,628.7%
The company's net margin has shrunk by 126% YoY but it has surged by 51% QoQ
ALGS's gross profit has dropped by 76% year-on-year and by 17% since the previous quarter
ALGS's revenue has dropped by 76% year-on-year and by 17% since the previous quarter
Aligos Therapeutics's net income has surged by 59% QoQ and by 47% YoY
Price vs fundamentals
How does ALGS's price correlate with its fundamentals
Growth
What is Aligos Therapeutics's growth rate over time
Valuation
What is Aligos Therapeutics stock price valuation
P/E
N/A
P/B
0.31
P/S
15.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-9.26
Aligos Therapeutics's EPS has soared by 61% YoY and by 51% from the previous quarter
Aligos Therapeutics's equity has surged by 95% YoY
The stock's price to book (P/B) is 79% less than its 5-year quarterly average of 1.5
The stock's price to sales (P/S) is 85% less than its 5-year quarterly average of 98.3 and 40% less than its last 4 quarters average of 25.1
ALGS's revenue has dropped by 76% year-on-year and by 17% since the previous quarter
Efficiency
How efficient is Aligos Therapeutics business performance
Aligos Therapeutics's ROS has plunged by 191% YoY but it has increased by 37% from the previous quarter
The return on equity has surged by 71% since the previous quarter and by 28% year-on-year
ALGS's return on assets has surged by 62% since the previous quarter and by 40% year-on-year
The company's return on invested capital has surged by 60% YoY and by 39% QoQ
Dividends
What is ALGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALGS.
Financial health
How did Aligos Therapeutics financials performed over time
ALGS's quick ratio has surged by 178% since the previous quarter and by 22% year-on-year
ALGS's current ratio has surged by 164% since the previous quarter and by 21% year-on-year
The company's debt is 93% lower than its equity
ALGS's debt to equity has soared by 124% QoQ but it has shrunk by 61% YoY
Aligos Therapeutics's equity has surged by 95% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.